Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Haematology International Journal Research Article 25 min read

Anemia and Erythropoietin in HIV: A Multifaceted Review

Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu*
* Corresponding author
ISSN: 2578-501X  10.23880/hij-16000244  Received: March 04, 2024  Published: April 01, 2024
 — views
 92 references
PDF
Keywords
Anemia Erythropoietin HIV Hematopoiesis Co-infection Pathogenesis Clinical Implications
Abstract

Anemia stands as a significant and multifaceted complication in the landscape of HIV, introducing a dynamic interplay of viral, immune, and hematopoietic factors. This comprehensive review navigates the intricate relationship between anemia and erythropoietin in the context of HIV, elucidating the pathogenesis, clinical implications, and evolving treatment paradigms. With an emphasis on the co-infection dynamics, hematopoietic pathogenesis, and the pivotal role of erythropoietin, this review explores the multifaceted nature of anemia in HIV, providing a holistic understanding crucial for effective management. The clinical implications extend beyond the hematological realm, impacting overall health and underscoring the need for tailored treatment strategies. Moreover, this review delves into evolving interventions, including erythropoiesis-stimulating agents and novel therapies, offering insights into the future of anemia management in the complex landscape of HIV. Through a critical examination of current knowledge and identification of research gaps, this review serves as a comprehensive resource for clinicians, researchers, and healthcare providers navigating the intricate terrain of anemia and erythropoietin in the context of HIV infection.

Emmanuel Ifeanyi Obeagu1* and Getrude Uzoma Obeagu2

context of HIV infection.

Introduction

Human Immunodeficiency Virus (HIV) infection remains a global health challenge, with an estimated 38 million people living with the virus worldwide. While advances in antiretroviral therapy (ART) have significantly improved the life expectancy and quality of life for individuals with HIV, the complex interplay between the virus and various physiological systems continues to present multifaceted clinical manifestations. Among these manifestations, anemia emerges as a prevalent and intricate complication, posing significant challenges to both clinicians and patients. The epidemiology of anemia in individuals with HIV is noteworthy, with prevalence rates significantly higher than in the general population. Anemia not only exacerbates the burden of disease but also serves as a marker of disease progression and a predictor of poorer outcomes. Understanding the underlying mechanisms driving anemia in the context of HIV is crucial for effective management. Hematopoietic pathogenesis, influenced by viral replication, immune activation, and cytokine dysregulation, forms a complex nexus that demands meticulous investigation [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22].

Co-infection dynamics further complicate the landscape of anemia in HIV. The high prevalence of co-infections, such as tuberculosis and viral hepatitis, introduces additional layers of complexity, necessitating a tailored approach to address the unique challenges posed by these synergistic forces. Consequently, a comprehensive review of anemia in HIV must consider the broader context of co-infections and their impact on hematological health. The pivotal role of erythropoietin, the hormone responsible for regulating red blood cell production, cannot be overstated in the context of HIV-associated anemia. The delicate balance between erythropoietin levels, inflammation, and viral factors influences the development and progression of anemia in individuals living with HIV. Understanding this intricate relationship is fundamental to devising targeted therapeutic strategies that address the root causes of anemia. Beyond its hematological consequences, anemia in the context of HIV carries substantial clinical implications. Increased cardiovascular risks, compromised immune function, and diminished quality of life underscore the urgency of effective management strategies. As such, clinicians are faced with the challenge of navigating not only the hematological aspects of anemia but also its broader impact on the overall health and well-being of individuals with HIV. Evolving treatment paradigms represent a beacon of hope in the management of anemia in the HIV population. Traditional interventions, including erythropoiesis-stimulating agents and iron supplementation, are complemented by emerging therapies that promise to revolutionize the approach to anemia. This review aims to critically examine these interventions, providing insights into their efficacy, safety, and potential implications for clinical practice [23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50].

Hematopoietic Pathogenesis in HIV

The hematopoietic system, responsible for the production of blood cells, is intricately intertwined with the pathogenesis of HIV infection. The impact of the virus on hematopoiesis extends beyond the traditional understanding of immune suppression, manifesting as a complex interplay between viral replication, immune dysregulation, and cytokine-mediated effects. HIV targets CD4+ T cells, the central orchestrators of the immune response, leading to their depletion. Within the bone marrow, home to hematopoietic stem and progenitor cells, the direct and indirect effects of viral replication disrupt the delicate balance of cell differentiation. This disruption results in impaired erythropoiesis, the process of red blood cell formation, contributing to the development of anemia. Persistent immune activation is a hallmark of chronic HIV infection, leading to an increased production of pro- inflammatory cytokines. Elevated levels of cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) create a pro-inflammatory microenvironment within the bone marrow. This inflammatory milieu negatively influences hematopoietic stem cells, impairing their ability to differentiate into mature blood cells, including erythrocytes [51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61].

Erythropoietin, a key regulator of red blood cell production, is influenced by the immune response and inflammatory signals. In HIV infection, dysregulation of erythropoietin production occurs as a result of both direct viral effects and the systemic inflammation. The impaired response to anemia due to altered erythropoietin dynamics further exacerbates the hematopoietic challenges faced by individuals with HIV. Beyond erythropoiesis, HIV affects other hematopoietic lineages, including megakaryocytes responsible for platelet production. Thrombocytopenia, commonly observed in HIV, reflects the impact of viral infection on megakaryocyte function. The reduction in platelet levels contributes to the overall hematopoietic compromise seen in individuals with HIV-associated anemia. HIV-induced alterations in the bone marrow microenvironment further contribute to hematopoietic pathogenesis. Changes in stromal cells, supportive niche cells within the bone marrow, disrupt the optimal conditions required for effective hematopoiesis. This microenvironmental dysregulation contributes to the overall impairment of blood cell production [62, 63, 64, 65, 66, 67, 68, 69].

Co-infection Dynamics

The landscape of HIV infection is often characterized by the intricate web of co-infections that individuals may encounter, significantly influencing the dynamics of anemia. Co-infections not only complicate the clinical management of HIV but also contribute synergistically to hematological challenges, necessitating a comprehensive understanding of these complex interactions. Tuberculosis (TB), a common co- infection in individuals with HIV, adds a layer of complexity to hematologic manifestations. The mycobacterium causing TB directly invades the bone marrow, impacting hematopoietic stem cells and impeding erythropoiesis. The combined effects of HIV and TB synergistically contribute to anemia, exacerbating the hematologic compromise observed in these dual-infected individuals. Co-infection with viral hepatitis, particularly hepatitis B (HBV) and hepatitis C (HCV), is prevalent in the HIV population. These hepatotropic viruses induce chronic liver inflammation, impacting the production and clearance of blood cells. Hematopoietic strain arises from compromised liver function, influencing erythropoiesis and contributing to the development of anemia in individuals co-infected with HIV and viral hepatitis [70, 71, 72, 73, 74, 75, 76, 77].

In regions where malaria is endemic, co-infection with HIV and Plasmodium species introduces a formidable challenge. Malaria-induced hemolysis, coupled with the immunosuppressive effects of HIV, significantly amplifies the burden of anemia. The bidirectional interaction between these two infections creates a synergistic impact on the hematopoietic system. Sexually transmitted infections, including syphilis, are prevalent among individuals with HIV. The spirochete Treponema pallidum can directly invade the bone marrow, causing disruption to hematopoiesis. Co- infection with syphilis complicates the hematologic picture in HIV, potentially contributing to anemia through direct bone marrow involvement. Co-infections with parasitic organisms, such as hookworms or schistosomes, are common in HIV-endemic regions. These parasites can directly affect erythrocyte survival and function, exacerbating anemia in individuals living with HIV. The combined impact of parasitic and viral infections poses a formidable challenge to maintaining hematologic homeostasis. Co-infections in HIV contribute to immune modulation, influencing the systemic inflammatory response. The immune dysregulation induced by co-infections further amplifies the pro-inflammatory environment, affecting the bone marrow and erythropoiesis. This immune modulation can lead to anemia, representing a complex interplay between infectious agents and the host’s immune response [78].

Role of Erythropoietin in HIV-Associated Anemia

Erythropoietin (EPO), a glycoprotein hormone produced primarily in the kidneys, plays a pivotal role in the regulation of red blood cell (RBC) production. In the context of HIV infection, the intricate relationship between EPO and anemia involves multifaceted interactions that extend beyond the traditional understanding of hematopoiesis. HIV induces a state of chronic immune activation and inflammation, impacting various organ systems, including the kidneys, where EPO is predominantly synthesized. The dysregulation of the immune response in HIV influences EPO production directly, disrupting the finely tuned balance required for optimal erythropoiesis. Consequently, compromised EPO production contributes to the development and perpetuation of anemia in individuals living with HIV. In the setting of HIV infection, the normal physiological response of EPO to anemia is often impaired. The virus’s direct impact on bone marrow and hematopoietic stem cells, coupled with the systemic inflammation, interferes with the responsiveness of erythroid progenitor cells to EPO signals. This impaired EPO response contributes to inadequate compensatory mechanisms, exacerbating the anemic state [79, 80, 81, 82, 83, 84].

Elevated levels of pro-inflammatory cytokines, characteristic of chronic HIV infection, further disrupt EPO dynamics [85]. Inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) negatively modulate EPO synthesis and responsiveness. This cytokine- induced EPO resistance exacerbates anemia, creating a challenging environment for erythropoiesis. HIV-associated anemia often involves alterations in iron metabolism, impacting the availability of iron for hemoglobin synthesis. EPO’s effectiveness is closely linked to sufficient iron levels, and disturbances in iron homeostasis contribute to the impaired utilization of EPO. Addressing iron deficiency becomes a crucial component in optimizing EPO’s role in mitigating anemia in individuals with HIV. Recognizing the diminished endogenous EPO response, exogenous EPO supplementation has been explored as a therapeutic intervention for HIV-associated anemia. Erythropoiesis- stimulating agents (ESAs) like recombinant human EPO have been employed to stimulate RBC production. However, the clinical use of ESAs in HIV requires careful consideration due to potential safety concerns, including cardiovascular risks and concerns about viral replication. The use of EPO in the management of HIV-associated anemia is not without challenges. Striking a balance between optimizing erythropoiesis and avoiding potential risks, such as thromboembolic events, requires a nuanced approach. Individualized treatment plans, considering the patient’s overall health, comorbidities, and HIV disease stage, become imperative when incorporating EPO into the therapeutic arsenal [86, 87, 88, 89].

Clinical Implications and Complications

Anemia in the context of HIV infection extends its influence far beyond hematological concerns, carrying profound clinical implications and complications that impact the overall health and well-being of affected individuals. Anemia in HIV has been linked to an increased risk of cardiovascular complications [90]. The diminished oxygen-carrying capacity of the blood, coupled with the chronic inflammatory state characteristic of HIV, contributes to cardiovascular strain. Individuals with HIV-associated anemia may experience a heightened susceptibility to conditions such as ischemic heart disease and heart failure, emphasizing the need for vigilant cardiovascular monitoring and management. Anemia exacerbates the immune compromise inherent in HIV infection. Reduced oxygen delivery to tissues can impede the proper functioning of immune cells, impairing their ability to mount an effective defense against opportunistic infections. This interplay between anemia and immune compromise underscores the importance of addressing hematologic parameters to maintain overall immune health in individuals living with HIV. The impact of anemia on the quality of life in individuals with HIV is substantial. Fatigue, weakness, and decreased exercise tolerance are common manifestations, impairing daily functioning and diminishing overall well-being. Addressing anemia becomes crucial not only for medical reasons but also to enhance the quality of life and ensure optimal adherence to antiretroviral therapy (ART) regimens.

Anemia has been associated with cognitive impairment in the general population, and this association is particularly pertinent in the context of HIV. Individuals with HIV-associated anemia may be at an increased risk of neurological complications, including cognitive decline and neurocognitive disorders. Timely intervention to address anemia may contribute to preserving cognitive function in this vulnerable population. Anemia serves as a prognostic marker in individuals with HIV, with numerous studies demonstrating its association with increased mortality. The presence of anemia has been linked to accelerated disease progression and a higher risk of mortality, emphasizing the critical importance of addressing hematologic parameters in the comprehensive care of individuals living with HIV. Anemia can pose challenges to the adherence and efficacy of ART. Fatigue and diminished functional capacity may contribute to non-adherence to medication regimens, compromising the long-term control of HIV. Effective management of anemia is therefore integral to optimizing the outcomes of ART and ensuring the sustained suppression of viral replication. Anemia can have implications for reproductive health in individuals with HIV. Pregnancy, already a complex scenario in the context of HIV, becomes further complicated when anemia is present. Addressing and managing anemia in reproductive-age individuals is essential to mitigate potential risks to both maternal and fetal health [90].

Evolving Treatment Strategies

Traditional approaches to anemia management in HIV have involved the use of erythropoiesis-stimulating agents, such as recombinant human erythropoietin. ESAs stimulate red blood cell production and have been effective in improving hemoglobin levels in certain populations. However, their use in HIV requires careful consideration due to concerns about potential adverse effects, including thromboembolic events [91, 92]. Given the intricate relationship between anemia and altered iron metabolism in HIV, strategies addressing iron deficiency have gained prominence. Iron supplementation, either orally or intravenously, is employed to correct iron deficits and enhance the efficacy of erythropoiesis. However, the careful assessment of iron status is crucial, as excessive iron can contribute to oxidative stress and may be detrimental in certain cases. Effective viral suppression through optimized ART regimens has indirect but significant benefits on anemia in individuals with HIV. Restoring immune function and reducing systemic inflammation contribute to improved erythropoiesis. As treatment paradigms for HIV continue to evolve, emphasis on early and sustained viral suppression remains integral to anemia management. With the recognition of the inflammatory component in HIV-associated anemia, novel therapies targeting specific inflammatory pathways are under investigation. Agents that modulate cytokine activity, such as anti-inflammatory biologics, hold promise in ameliorating the chronic inflammatory state and potentially improving erythropoietin responsiveness.

The heterogeneity in the presentation and etiology of anemia in HIV underscores the need for personalized treatment approaches. Tailoring interventions based on individual patient characteristics, including viral load, CD4 count, co-infections, and genetic factors, allows for precision in addressing the diverse etiologies contributing to anemia. Co-infections, common in individuals with HIV, significantly impact anemia. Evolving treatment strategies recognize the importance of concurrently managing co- infections such as tuberculosis, viral hepatitis, and parasitic infections. Coordinated care that addresses both HIV and associated co-infections is essential for comprehensive anemia management. Recognizing anemia as a critical aspect of overall health in individuals with HIV, the integration of hematologic and HIV care has become pivotal. Coordinated efforts between hematologists and HIV specialists ensure a holistic approach, addressing both viral control and hematologic parameters for optimal patient outcomes [91].

Conclusion

The intricate relationship between anemia and HIV represents a multifaceted challenge that extends beyond the boundaries of traditional hematological concerns. The hematopoietic pathogenesis in HIV sheds light on the complex interplay between viral replication, immune activation, and cytokine dysregulation, impacting erythropoiesis and contributing to the development of anemia. Co-infections, including tuberculosis, viral hepatitis, and parasitic diseases, further amplify the challenges, emphasizing the need for a tailored and comprehensive approach to anemia management. Erythropoietin, as a key regulator of red blood cell production, plays a crucial role in the context of HIV-associated anemia. The impaired EPO response, influenced by viral factors and inflammatory cytokines, contributes to the complexity of anemia pathophysiology. Evolving treatment strategies, ranging from traditional erythropoiesis-stimulating agents to innovative approaches targeting inflammatory pathways and personalized interventions, highlight the dynamic nature of therapeutic advancements. The clinical implications of anemia in HIV extend across various domains, impacting cardiovascular health, immune function, quality of life, and even reproductive health. Addressing anemia becomes a critical component not only for hematological well-being but also for optimizing overall health outcomes and mitigating mortality risks.

References

  1. Patel P, Raizes E, Broyles LN (2020) Human Immunodeficiency Virus Infection. In Edward TR, Tom S, David RH, Naomi EA, Timothy PE (Eds.), Hunter’s Tropical Medicine and Emerging Infectious Diseases. 10th (Edn.), Elsevier, pp: 232-266.
  2. Younai FS (2013) Thirty Years of the Human Immunodeficiency Virus Epidemic and Beyond. Int J Oral Sci 5(4): 191-199.
  3. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU (2022) Under Nutrition among HIV Exposed Uninfected Children a Review of African Perspective. Madonna University Journal of Medicine and Health Sciences 2(3): 120-127.
  4. Obeagu EI, Alum EU, Obeagu GU (2023) Factors Associated with Prevalence of HIV among Youths a Review of Africa Perspective. Madonna University Journal of Medicine and Health Sciences 3(1): 13-18.
  5. Obeagu EI (2023) A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University Journal of Medicine and Health Sciences 3(1): 7-12.
  6. Obeagu EI, Obeagu GU (2023) An Update on Premalignant Cervical Lesions and Cervical Cancer Screening Services among HIV Positive Women. J Pub Health Nutri 6 (2): 141.
  7. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, et al. (2021) Prevalence of Malaria with Anaemia and HIV Status in Women of Reproductive Age in Onitsha, Nigeria. Journal of Pharmaceutical Research International 33(4): 10-19.
  8. Obeagu EI (2017) Evaluation of Laboratory Logistics Management Information System in HIV/AIDS Comprehensive Health Facilities in Bayelsa State Nigeria. Int J Curr Res Med Sci 3(1): 21-38.
  9. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO (2023) Factors Contributing to Low Utilization of HIV Counseling and Testing Services. Int J Curr Res Med Sci 9(2): 1-5.
  10. Obeagu EI, Obeagu GU (2022) An Update on Survival of People Living with HIV in Nigeria. J Pub Health Nutri 5(6): 129.
  11. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, et al. (2021) Facilitators and Barriers to Retention in HIV Care among HIV Infected MSM Attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International 33(52B): 10-19.
  12. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, et al. (2021) Prevalence of Malaria with Anaemia and HIV Status in Women of Reproductive Age in Onitsha, Nigeria. Journal of Pharmaceutical Research International 33(4): 10-19.
  13. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, et al. (2020) TB Infection Control in TB/HIV Settings in Cross River State Nigeria Policy Vs Practice. Journal of Pharmaceutical Research International 32(22): 101- 119.
  14. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC (2016) Determination of Haematocrit Level and Iron Profile Study among Persons Living with HIV in Umuahia Abia State Nigeria. J Bio Innov 5(4): 464-471.
  15. Ifeanyi OE, Obeagu GU (2015) The Values of Prothrombin Time among HIV Positive Patients in FMC Owerri. Int J Curr Microbiol App Sci 4(4): 911-916.
  16. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, et al. (2016) Knowledge of Preventive Measures and Management of HIV/AIDS Victims among Parents in Umuna Orlu Community of Imo State Nigeria. Int J Adv Res Biol Sci 3(10): 55-65.
  17. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, et al. (2017) HIV and TB Co-Infection among Patients Who used Directly Observed Treatment Short-Course Centres in Yenagoa Nigeria. IOSR J Pharm Biol Sci 12(4): 70-75.
  18. Oloro OH, Oke TO, Obeagu EI (2022) Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences 2(3): 110-119.
  19. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, et al. (2016) Change in Lipid Peroxidation Marker (MDA) and Non Enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State Nigeria. J Bio Innov 5(1): 24-30.
  20. Igwe CM, Obeagu IE, Ogbuabor OA (2022) Clinical Characteristics of People Living With HIV/AIDS on ART in 2014 at Tertiary Health Institutions in Enugu, Nigeria. J Pub Health Nutri 5(6): 130.
  21. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI (2015) The Values of Activated Partial Thromboplastin Time (APTT) among HIV Positive Patients in FMC Owerri. Int J Curr Res Aca Rev 3(4): 139-144.
  22. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO (2018) Hematologica Indices of HIV Seropositive Subjects In Nnamdi Azikiwe University Teaching Hospital (NAUTH) Nnewi. Ann Clin Lab Res 6(1): 1-4.
  23. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF (2017) Impact of Prevention of Mother to Child Transmission (PMTCT) of HIV on Positivity Rate in Kafanchan Nigeria. Int J Curr Res Med Sci 3(2): 28-34.
  24. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI (2023) Alarming Rise in HIV Cases in Pakistan Challenges and Future Recommendations at Hand. Health Science Reports 6(8): e1450.
  25. Obeagu EI, Amekpor F, Scott GY (2023) An Update of Human Immunodeficiency Virus Infection Bleeding Disorders. J Pub Health Nutri 6(1): 139.
  26. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, et al. (2022) Prevention of New Cases of Human Immunodeficiency Virus Pragmatic Approaches of Saving Life in Developing Countries. Madonna University Journal of Medicine and Health Sciences 2(3): 128-134.
  27. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL (2022) Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International 34(3A): 29-34.
  28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, et al. (2020) Cascade Variabilities in TB Case Finding among People Living with HIV and the Use of IPT Assessment in Three Levels of Care in Cross River State Nigeria. Journal of Pharmaceutical Research International 32(24): 9-18.
  29. Jakheng SP, Obeagu EI (2022) Seroprevalence of Human Immunodeficiency Virus Based on Demographic and Risk Factors among Pregnant Women Attending Clinics in Zaria Metropolis Nigeria. J Pub Health Nutri 5(8): 127.
  30. Obeagu EI, Obeagu GU (2023) A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int J Adv Res Biol Sci 10(9): 135- 142.
  31. Obeagu EI, Onuoha EC (2023) Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int J Adv Res Biol Sci 10(9): 128-134.
  32. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP (2017) Haematological Indices of Malaria Patients Coinfected with HIV in Umuahia. Int J Curr Res Med Sci 3(5): 100-104.
  33. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, et al. (2022) Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis Kaduna State Nigeria. South Asian Journal of Research in Microbiology 13(2): 26-31.
  34. Viola N, Kimono E, Nuruh N, Obeagu EI (2023) Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences 3(2): 7-14.
  35. Okorie HM, Ifeanyi OE, Henry OHC, Nchekwubedi CS (2020) Comparative Study of Enzyme Linked Immunosorbent Assay (ELISA) and Rapid Test Screening Methods on HIV, HBsAg, HCV and Syphilis among Voluntary Donors in Owerri Nigeria. J Clin Commun Med 2(3): 180-183.
  36. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, et al. (2021) Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case Controlled Study. Journal of Pharmaceutical Research International 33(47A): 78-84.
  37. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K (2023) Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth 6(1): 203-211.
  38. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, et al. (2022) Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases 10(4): 1-7.
  39. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi- Chigbu AC (2021) Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International 33(57A): 360-368.
  40. Igwe MC, Obeagu EI, Ogbuabor AO (2022) Analysis of the Factors and Predictors of Adherence to Healthcare of People Living with HIV/Aids in Tertiary Health Institutions in Enugu State. Madonna University journal of Medicine and Health Sciences 2(3): 42-57.
  41. Madekwe CC, Madekwe CC, Obeagu EI (2022) Inequality of Monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University Journal of Medicine and Health Sciences 2(3): 6-15.
  42. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, et al. (2023) Weights of Infants Born to Hiv Infected Mothers: A Prospective Cohort Study in Federal Medical Centre, Owerri, Imo State. European Journal of Pharmaceutical and Medical Research 10(8): 564-568.
  43. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, et al. (2015) Biochemical Alterations in Adult Hiv Patients on Antiretrqviral Therapy. World Journal of Pharmacy and Pharmaceutical Sciences 4(3): 153-160**.**
  44. Obeagu EI, Obeagu GU (2015) Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int J Curr Res Biosci Plant Biol 2(4): 45-49.
  45. Obeagu EI, Nwosu DC (2019) Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence. Int J Curr Res Chem Pharm Sci 6(12): 45-48.
  46. Obeagu EI, Scott GY, Amekpor F, Obeagu GU (2023) Implications of CD4/CD8 Ratios in Human Immunodeficiency Virus Infections. Int J Curr Res Med Sci 9(2): 6-13.
  47. Obeagu EI, Ochei KC, Okeke EI, Anode AC (2016) Assessment of the Level of Haemoglobin and Erythropoietin in Persons Living with HIV in Umuahia. Int J Curr Res Med Sci 2(4): 29-33.
  48. Ifeanyi OE, Obeagu GU (2015) The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int J Curr Microbiol App Sci 4(4): 906-910.
  49. Obeagu EI, Okeke EI, Anonde Andrew C (2016) Evaluation of Haemoglobin and Iron Profile Study among Persons Living with HIV in Umuahia, Abia State, Nigeria. Int J Curr Res Biol Med 1(2): 1-5.
  50. Alum EU, Ugwu OP, Obeagu EI, Okon MB (2023) Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS) 3(2): 28-31.
  51. Obeagu EI, Obeagu GU, Paul-Chima UO (2023) Stigma Associated With HIV AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP) 3(2): 64-67.
  52. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB (2023) HIV Infection and Cardiovascular Diseases: The Obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS) 3(2): 95-99.
  53. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI (2018) A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research 1(2): 8-14.
  54. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB (2014) Assessment of Some Haematological and Biochemical Parametrs in HIV Patients before Receiving Treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci 5(2): 825-830.
  55. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC (2014) Pattern of Total White Blood Cell and differential Count Values in HIV Positive Patients Receiving Treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Sciences Biotechnology and Pharma Research 3(1): 186-189.
  56. Obeagu EI (2023) A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences 3(1): 7-12.
  57. Oloro OH, Obeagu EI (2022) A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research 10(5): 1-11.
  58. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, et al. (2015) Alterations in Superoxide Dismutiase, Vitamins C and E in HIV Infected Children in Umuahia, Abia State. International Journal of Advanced Research in Biological Sciences 2(11): 268-271.
  59. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV Resistance in Patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES) 3(2): 56-59.
  60. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC (2018) Vitamin D and Insulin Resistance in HIV Sero Positive Individuals in Umudike. Int J Curr Res Med Sci 4(2): 104-108.
  61. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK (2018) A Review on Blood Borne Viral Infections: Universal Precautions. Int J Adv Res Biol Sci 5(6): 60-66.
  62. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS (2018) Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord 1(2).
  63. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, et al. (2017) HIV and TB Co-infection among Patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci 12(4): 70-75.
  64. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, et al. (2021) Facilitators and Barriers to Retention in HIV Care among HIV Infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International 33(52B): 10-19.
  65. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA (2023) Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A Review. Medicine (Baltimore) 102(49): e36599.
  66. Obeagu EI, Okoroiwu IL, Obeagu G (2015) Molecular Mechanism and Systemic Response of Erythropoietin: A Review. Int J Adv Res Biol Sci 2(7): 58-62.
  67. Obeagu EI, Okoroiwu II, Ezimah AC (2016) Evaluation of Serum Erythropoietin Levels in Chronic Kidney Disease Patients in Federal Medical Centre, Umuahia, Nigeria. Int J Curr Res Biol Med 1(4): 15-21.
  68. Obeagu EI (2020) Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences 5(2): 22-28.
  69. Obeagu EI, Ezimah AC, Obeagu GU (2016) Erythropoietin in the Anaemias of Pregnancy: A Review. Int J Curr Res Chem Pharm Sci 3(3): 10-18.
  70. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI (2023) Distribution of ABO and Rhesus blood grouping with HIV Infection among Blood Donors in Ekiti State Nigeria. Medicine (Baltimore) 102(47): e36342.
  71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI (2023) Effect of Dolutegravir Regimen against other Regimens on some Hematological Parameters, CD4 Count and Viral Load of People Living with HIV Infection in South Eastern Nigeria. Medicine (Baltimore) 102(47): e35910.
  72. Opeyemi AA, Obeagu EI (2023) Regulations of Malaria in Children with Human Immunodeficiency Virus Infection: A Review. Medicine (Baltimore) 102(46): e36166.
  73. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, et al. (2023) Inclusion of Nutritional Counseling and Mental Health Services in HIV/AIDS Management: A Paradigm Shift. Medicine (Baltimore) 102(41): e35673.
  74. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI (2023) Alarming Rise in HIV Cases in Pakistan: Challenges and Future Recommendations at Hand. Health Sci Rep 6(8): e1450.
  75. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, et al. (2023) Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences 3(3).
  76. Obeagu EI, Ubosi NI, Uzoma G (2023) Storms and Struggles: Managing HIV Amid Natural Disasters. Int J Curr Res Chem Pharm Sci 10(11): 14-25.
  77. Obeagu EI, Obeagu GU (2023) Human Immunodeficiency Virus and Tuberculosis Infection: A Review of Prevalence of Associated Factors. Int J Adv Multidiscip Res 10(10): 56-62.
  78. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, et al. (2023) Reducing HIV Infection Rate in Women: A Catalyst to Reducing HIV Infection Pervasiveness in Africa. International Journal of Innovative and Applied Research 11(10): 1-6.
  79. Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO (2015) A Review on Erythropoietin Receptor (EpoR). Int J Adv Res Biol Sci 2(8): 80-84.
  80. Obeagu EI (2016) Erythrocyte Enumeration and Serum Erythropoietin in Chronic Kidney Disease Patients: A Study in Federal Medical Centre, Umuahia, Nigeria. International Journal of Advanced Research in Biological Sciences 3(7): 163-170.
  81. Ifeanyi OE (2015) A Review on Erythropoietin. Int J Adv Res Biol Sci 2(4): 35-47.
  82. Obeagu EI (2024) Maximizing Longevity: Erythropoietin’s Impact on Sickle Cell Anemia Survival Rates. Ann Med Surg 86(3): 1570-1574.
  83. Ifeanyi OE, Uzoma OG (2018) A Review on Erythropietin in Pregnancy. J Gynecol Womens Health 8(3): 555740.
  84. Obeagu EI, Okoroiwu IL, Obeagu GU (2022) Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm Sci 9(1): 7-13.
  85. Lakkavaram A, Lundie RJ, Do H, Ward AC, de Koning- Ward TF (2020) Acute Plasmodium Berghei Mouse Infection Elicits Perturbed Erythropoiesis with Features that Overlap with Anemia of Chronic Disease. Front Microbiol 11: 702.
  86. Obeagu EI, Obeagu GU, Amilo GI (2018) Haematological Changes in Patients of Chronic Kidney Disease in Umuahia, Abia State, Nigeria. Curr Trends Biomedical Eng & Biosci 11(1): 34-37.
  87. Obeagu EI, Okoroiwu IL, Azuonwu O (2018) An Update on Hypoxic Regulation of Iron Homeostasis and Bone Marrow Environment. Int J Curr Res Med Sci 4(10): 42- 48.
  88. Obeagu EI (2020) Blood Transfusion: A Powerful Process of Saving Anaemic Patients. EC Emergency Medicine and Critical Care 4(7): 33-40.
  89. Obeagu EI, Obeagu GU, Onuigwe FU (2024) Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. International Journal of Innovative and Applied Research 12(1): 72-82.
  90. Redig AJ, Berliner N (2013) Pathogenesis and Clinical Implications of HIV-Related Anemia in 2013. Hematology Am Soc Hematol Educ Program 2013(1): 377-381.
  91. Rogers J, Gallaher EJ, Dingli D (2018) Personalized ESA Doses for Anemia Management in Hemodialysis Patients with End‐stage Renal Disease. System Dynamics Review 34(1-2): 121-153.
  92. Van Remoortel H, Laermans J, Avau B, Bekkering G, Georgsen J, et al. (2021) Effectiveness of Iron Supplementation with or without Erythropoiesis- Stimulating Agents on Red Blood Cell Utilization in Patients with Preoperative Anaemia Undergoing Elective Surgery: A Systematic Review and Meta-Analysis. Transfus Med Rev 35(2): 103-124.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{emmanuel2024,
  title   = {Anemia and Erythropoietin in HIV: A Multifaceted Review},
  author  = {Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu},
  journal = {Haematology International Journal},
  year    = {2024},
  volume  = {8},
  number  = {1},
  doi     = {10.23880/hij-16000244}
}
Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu (2024). Anemia and Erythropoietin in HIV: A Multifaceted Review. Haematology International Journal, 8(1). https://doi.org/10.23880/hij-16000244
TY  - JOUR
TI  - Anemia and Erythropoietin in HIV: A Multifaceted Review
AU  - Emmanuel Ifeanyi Obeagu* and Getrude Uzoma Obeagu
JO  - Haematology International Journal
PY  - 2024
VL  - 8
IS  - 1
DO  - 10.23880/hij-16000244
ER  -